Neko Health's $700M Series C: A 4x Markup in 18 Months, But Whose $7 Billion Is It?

TL;DR: Neko Health, the full-body scanning startup co-founded by Spotify's Daniel Ek, raised $700 million in a Series C led by Lightspeed Venture Partners and O.G. Venture Partners. Media outlets, not the company, are reporting a valuation near $7 billion, up roughly 4x from the $1.8 billion post-money price Neko confirmed 18 months earlier (TechCrunch, July 15, 2026). I want you to see the gap between that number and the company's actual scan volume before you get excited about secondary exposure.

Let's start with what I know for certain, because the certain part is thinner than the headline suggests. A lot of coverage this week is treating "$7 billion" as fact. It isn't, at least not yet, and the difference between a confirmed number and a reported one is exactly where I want to spend your attention.

The Deal, Line by Line

Neko Health closed a $700 million Series C on July 15, 2026. Lightspeed Venture Partners and O.G. Venture Partners led the round. Existing backers Atomico, General Catalyst, Lakestar, Liberty City Ventures, Positive Sum, and BDT & MSD returned. The round also drew a cluster of celebrity checks: Mark Zuckerberg, Maria Sharapova, and will.i.am are named participants, according to TechCrunch's reporting.

Here's the part you need to hold onto: the $700 million figure is company-confirmed. The ~$7 billion valuation is not. It's a number reported by TechCrunch and other outlets, sourced to people familiar with the deal, not a figure Neko Health has put its own name on in a press release. That distinction matters more in this deal than in most, because of how much weight the valuation number is being asked to carry against very little disclosed revenue.

Now the math on the markup. In January 2025, Neko raised $260 million at a $1.8 billion post-money valuation. That number was also TechCrunch-confirmed and sourced on the record at the time (TechCrunch, January 22, 2025). Eighteen months later, the reported valuation sits near $7 billion. Divide the two and you get a markup of roughly 3.9x. Round it, and everyone in the deal is calling it 4x.

Four times your valuation in a year and a half is not normal for a company selling a consumer health product with no US location and no insurance code attached to it. I want to be precise about that, because "not normal" isn't the same as "wrong." It's a flag. Flags don't tell you to walk away. They tell you to ask harder questions before you write a check, or before you let someone else write one on your behalf through a feeder fund.

One more mechanical point worth stating plainly, since it gets lost in headline math. A post-money valuation is a negotiated price between the company and the new lead investors, set partly by how much capital the company wants to raise and how much dilution the founders will accept. It is not a market-clearing price the way a public stock quote is. Two different Series C investors could have offered Neko two different valuations for the same $700 million check, depending on liquidation preferences, board seats, and pro-rata rights. The $7 billion figure reported this week reflects terms Lightspeed and O.G. Venture Partners negotiated. It doesn't mean an outside buyer today would pay $7 billion for the whole company, because there is no open market for Neko Health shares.

Metric	January 2025 (Series B)	July 2026 (Series C)
Capital raised	$260M	$700M
Valuation	$1.8B (company-confirmed)	~$7B (media-reported)
Time elapsed	—	18 months
Implied markup	—	~3.9x

My Contrarian Read: Show Me the Revenue

I've watched enough late-stage rounds price off momentum instead of unit economics to know what questions to ask when a valuation quadruples faster than the underlying business could plausibly grow. So let's run Neko's numbers the way I'd run them for a client, not the way a term sheet deck runs them.

Neko has performed more than 100,000 scans since its February 2023 launch, across a small number of clinics in the UK and Sweden. That's roughly ten locations, by the company's own account, after three-plus years in business. A scan costs £299 in the UK, or 2,750 SEK in Sweden, which works out to about $341 at current exchange rates. Multiply 100,000 scans by that price and you land somewhere in the neighborhood of $30 million to $35 million in cumulative revenue, spread across the full three-plus years of operation. That's lifetime revenue, not annual revenue. Even if you assume the true annual run rate is a fraction of that cumulative figure concentrated in the most recent twelve months, you are nowhere near a number that conventionally supports a $7 billion price tag using any revenue multiple a public-market investor would recognize.

Neko will tell you, correctly, that 75% of members prepay for next year's scan. That's a real signal of retention and product satisfaction, and I don't dismiss it. Recurring revenue from a loyal base is worth more per dollar than one-time transactional revenue. But retention among 100,000 people in two European countries is a different animal from a scaled, insurance-adjacent US health business. Neko has zero open US clinics as of this raise. FDA and state-level approval processes are still pending. The growth story that would justify a $7 billion valuation is a US expansion story that hasn't happened yet. Investors are pricing the plan, not the results.

Do the comparison a different way and the gap gets harder to explain away. Public diagnostic-imaging and health-screening companies typically trade at low single-digit multiples of revenue. Even generous private-market multiples for a fast-growing consumer health brand rarely stretch past 15x to 20x forward revenue without a subscription model with proven expansion economics behind it. Apply the aggressive end of that range to Neko's likely current annual revenue, probably somewhere in the high single-digit millions to low tens of millions given the clinic count and scan pricing, and you get a defensible valuation in the hundreds of millions to perhaps $1 billion to $2 billion. You do not get to $7 billion without assuming a US rollout that hasn't started, at a pace and margin that hasn't been demonstrated anywhere Neko currently operates.

This is the pattern I want you to notice, because it's bigger than one Swedish scanning company. Across 2025 and 2026, I've tracked a run of late-stage private rounds where valuations triple or quadruple in 12 to 18 months on companies with modest, sometimes undisclosed, revenue bases. In many of these deals, celebrity or strategic-name investors show up specifically in ways that generate press coverage reinforcing the price. Zuckerberg's name in a health-tech cap table generates headlines. Headlines generate inbound interest from the next round of investors, who don't want to miss a deal their peers are already excited about. That dynamic is not new to venture capital. It has, however, historically preceded painful markdowns when the follow-on growth doesn't match the round-over-round velocity. I watched this movie in direct-to-consumer retail around 2015, again in proptech around 2021, and now I'm watching a new cast perform the same script in consumer health diagnostics.

I've written before about how concentrated the current AI-driven venture capital market has become. The same herd dynamic that's driving 81% of Q1 2026 VC dollars into a narrow set of categories is visible here too. Capital is chasing a story, not always a spreadsheet, and a story with Daniel Ek, Mark Zuckerberg, and Maria Sharapova attached is an easy one to tell limited partners back home.

None of this means Neko Health is a bad company. Daniel Ek built Spotify into a company with real, audited revenue and a public listing. He's not a first-time founder chasing a narrative, and that history buys him real credibility with sophisticated investors. Co-founder Hjalmar Nilsonne and the clinical team have built a product with genuinely high member satisfaction, evidenced by that 75% prepayment rate. But "good company" and "$7 billion good" are two different claims, and right now only one of them has numbers behind it.

The Risk Section You Won't See in the Press Release

If you're an accredited investor weighing exposure to this round, whether through a secondary, an SPV, or a feeder fund marketed off the Neko name, walk through these risks before anything else.

No insurance reimbursement, anywhere. Neko's scans are cash-pay only. No public or private insurer in the UK, Sweden, or anywhere Neko plans to expand covers the cost. That caps the addressable market to people who can pay $341-plus out of pocket, repeatedly, for a product with no proven mortality benefit. Every dollar of Neko's revenue depends on discretionary consumer spending, not a reimbursement pipeline that would make growth more durable and predictable.

Unclear unit economics at scale. Ten clinics is a boutique footprint. Running a diagnostic clinic with radiologist-reviewed imaging is expensive. Real estate, imaging hardware, clinical staff, and physician review time all scale with volume in ways that a software business does not. Neko hasn't disclosed clinic-level margins, and I'd want to see them before assuming the model that works at ten locations survives at 100, let alone at the scale needed to justify $7 billion.

The overdiagnosis problem is a real medical criticism, not investor paranoia. The American College of Radiology has stated there is insufficient evidence to recommend total-body screening for people without symptoms. Full-body scans are prone to finding incidentalomas, which are incidental findings that look concerning but are usually harmless. Those findings can trigger unnecessary follow-up testing, biopsies, and patient anxiety without improving outcomes. Competitors Prenuvo and Ezra, priced between $1,000 and $2,500 per scan, face the identical clinical critique (AP News). This is a category-wide credibility risk, not a Neko-specific flaw. But it caps how fast any regulator or insurer will move toward legitimizing the category, and that timeline caps how fast the revenue story can catch up to the valuation story.

Illiquidity. This is the one investors underweight most. If you get exposure to Neko through a secondary purchase or an SPV, you are locked into an illiquid position with no public market, no guaranteed exit timeline, and no ability to sell if the next round reprices down. Pre-IPO exposure is a bet on two things happening in sequence. First, the company has to keep growing. Second, someone else has to want to buy your position later at a higher price. Neither is guaranteed, and the second one depends entirely on sentiment holding up long enough for an IPO or acquisition to materialize.

Stack those four risks together and you get a clearer picture of what you'd actually be buying: a concentrated bet on regulatory approval, US consumer adoption, and continued investor enthusiasm, all landing in roughly the same window of time.

What to Ask Before You Chase This Kind of Round

I'm not going to tell you to buy or avoid any specific fund, SPV, or secondary offering tied to Neko Health. What I will tell you is the diligence sequence I'd run, and that any credible platform offering you this exposure should be able to answer without flinching.

• What is the actual share price you're paying per unit of the underlying security, and what markup does that represent over the price the lead investors paid in this same round?
• How many layers of fees sit between your capital and the underlying equity? A feeder fund's carry stacked on top of an SPV's carry, stacked on top of a platform fee, can quietly eat a meaningful share of your eventual return.
• What rights do you actually hold? Common stock, preferred, or a synthetic instrument that tracks the value but carries none of the governance or liquidation preference?
• What is the realistic liquidity timeline, and what happens to your position if the company raises a down round before any exit event?
• Has the platform disclosed Neko's actual revenue figures, or are you being sold a narrative built on scan-volume totals and celebrity investor names?

If you're new to how pre-IPO and secondary access actually works, including the mechanics of platforms like Forge Global and EquityZen and what they can and can't get you into, I've laid out the structural tradeoffs in our pre-IPO secondary market guide, and a deeper dive into Forge specifically in our 2026 Forge Global review. Read those before you assume access equals opportunity, because access to a hot name and access to a fairly priced security are not the same thing.

Here's my bottom line. A $700 million check from Lightspeed and O.G. Venture Partners is real capital. Real capital doesn't move on vibes alone, and these firms did diligence I haven't seen and don't have access to. But the ~$7 billion number attached to that check is a media estimate sitting on top of a business that has done roughly 100,000 scans in three years, has no US clinic, and carries no path to insurance reimbursement. I'd rather you ask five sharp questions and pass on a hot deal than skip the questions and find out in 18 months that the next round priced down. Momentum is not a moat. Revenue is. Ask for the revenue before you ask for the allocation.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.